Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

* To determine the maximum tolerated dose (MTD) of temsirolimus that could be administered weekly in combination with pemetrexed. * To determine the dose-limiting toxicity (DLT) of temsirolimus and pemetrexed as well as other toxicities of this combination therapy. * To describe the response rate of the combination in patients with relapsed/refractory non-small cell lung cancer (NSCLC). * To describe phospho-Akt and phospho-S6 levels in circulating mononuclear cells before and after treatment. * To determine the response rates in patients with NSCLC when treated with temsirolimus and pemetrexed. * To evaluate progression-free survival in patients with NSCLC when treated with temsirolimus and pemetrexed. * To determine the one-year survival rates in patients with NSCLC when treated with temsirolimus and pemetrexed. * To describe phospho-Akt and phospho-S6 levels in circulating mononuclear cells before and after treatment.